|
2017 Conference Publication International HTA experience with targeted therapy approvals For lung cancerMaraiki, F., Byrnes, J., Tuffaha, H. and Hider, M. (2017). International HTA experience with targeted therapy approvals For lung cancer. ISPOR 20th Annual European Congress, Glasgow, United Kingdom, 4-8 November 2017. New York, NY USA: Elsevier. doi: 10.1016/j.jval.2017.08.335 |
|
2017 Conference Publication Improving patient access to novel cancer drugs in Australia: are we there yet?Tuffaha, Haitham and Scuffham, Paul (2017). Improving patient access to novel cancer drugs in Australia: are we there yet?. COSA's 44th Annual Scientific Meeting, Immunotherapy: Molecules and Mountains, Sydney, NSW Australia, 13-15 November 2017. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. |
|
2015 Conference Publication Health economic modelling for treatments and services in prostate cancer care: a master model for AustraliaGordon, Louisa, Tuffaha, Haitham, Scuffham, Paul and Lowe, Anthony (2015). Health economic modelling for treatments and services in prostate cancer care: a master model for Australia. 2nd Prostate Cancer World Congress (PCWC), Cairns, QLD, Australia, 17-21 August, 2015. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/bju.13196 |
|
2014 Conference Publication COST-EFFECTIVENESS AND VALUE OF INFORMATION ANALYSES OF NUTRITIONAL SUPPORT IN PREVENTING PRESSURE ULCERS IN HIGH RISK HOSPITALISED PATIENTSTuffaha, H. W., Shelley, R., Chaboyer, W., Gordon, L. G. and Scuffham, P. A. (2014). COST-EFFECTIVENESS AND VALUE OF INFORMATION ANALYSES OF NUTRITIONAL SUPPORT IN PREVENTING PRESSURE ULCERS IN HIGH RISK HOSPITALISED PATIENTS. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/j.jval.2014.08.2150 |
|
2012 Conference Publication COMPARATIVE COST UTILITY ANALYSIS OF PLERIXAFOR PLUS GCSF VERSUS CYCLOPHOSPHAMIDE PLUS GCSF AS SALVAGE MOBILIZATION REGIMENS IN MULTIPLE MYELOMA PATIENTSTuffaha, H. W., Hussein, A. A. and Abdel-Rahman, F. A. (2012). COMPARATIVE COST UTILITY ANALYSIS OF PLERIXAFOR PLUS GCSF VERSUS CYCLOPHOSPHAMIDE PLUS GCSF AS SALVAGE MOBILIZATION REGIMENS IN MULTIPLE MYELOMA PATIENTS. BMT Tandem Meeting, San Diego Ca, Feb 01-05, 2012. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/j.bbmt.2011.12.132 |
|
2012 Conference Publication THE EFFECTIVENESS AND COST EFFECTIVENESS OF PLERIXAFOR plus GCSF VERSUS GCSF +/- CHEMOTHERAPY AS SALVAGE MOBILIZATION REGIMENS IN LYMPHOMA AND MULTIPLE MYELOMA PATIENTSTuffaha, H. W., Hussein, A. A., Sharma, S., Abu-Jazar, H., Al-Rawi, O. S., Saad, A. M., Al-Zaben, A., Hussein, N. and Abdel-Rahman, F. A. (2012). THE EFFECTIVENESS AND COST EFFECTIVENESS OF PLERIXAFOR plus GCSF VERSUS GCSF +/- CHEMOTHERAPY AS SALVAGE MOBILIZATION REGIMENS IN LYMPHOMA AND MULTIPLE MYELOMA PATIENTS. BMT Tandem Meeting, San Diego Ca, Feb 01-05, 2012. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/j.bbmt.2011.12.130 |
|
2012 Conference Publication Adverse drug reactions in bone marrow transplant patientsNajjar, R., Tuffaha, H., Abdel-Rahman, F., Hussein, A. and Jazar, H. A. (2012). Adverse drug reactions in bone marrow transplant patients. 38th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT), Geneva, Switzerland, 1-4 April, 2012. London, United Kingdom: Nature Publishing Group. doi: 10.1038/bmt.2012.37 |
